U.S., Nov. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07911683) titled 'Study Evaluating the Efficacy and Safety of BGB-B2033 in Participants With Advanced Hepatocellular Carcinoma' on Oct. 27.
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of BGB-B2033 monotherapy in adults with hepatocellular carcinoma who have previously been treated with anti-programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) therapies.
Study Start Date: Nov. 30
Study Type: INTERVENTIONAL
Condition:
Hepatocellular Cancer
Liver Cancer
Hepatocellular Carcinoma
Intervention:
DRUG: BGB-B2033
Administered intravenously
Recruitment Status: NOT_YET_RECRUITING
Sponsor: BeOne Med...